Trial Profile
A Phase Ib Study to Evaluate the Safety and Tolerability of Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary) ; Carboplatin; Etoposide; Fluorouracil; Folinic acid; Gemcitabine; Oxaliplatin; Paclitaxel
- Indications Adenocarcinoma; Advanced breast cancer; Fallopian tube cancer; Gastric cancer; Head and neck cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Small cell lung cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer
- Focus Adverse reactions
- Sponsors AstraZeneca
- 04 Dec 2019 Status changed from active, no longer recruiting to completed.
- 08 Feb 2019 Planned End Date changed from 28 Jun 2019 to 31 Mar 2020.
- 08 Feb 2019 Planned primary completion date changed from 28 Jun 2019 to 31 Mar 2020.